CHIT1 and prostate cancer: Kukur et al. also described a significantly (p < 0.05) higher chitotriosidase activity in patients with primary prostate cancer (91.33 ± 8.32 nmol/mL/h), compared to those with biopsy-certified benign prostatic hyperplasia (69.72 ± 8.69 nmol/mL/h).